Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tuebingen, Germany.
Diagnostic and Interventional Neuroradiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tuebingen, Germany.
Sci Rep. 2019 Feb 13;9(1):1901. doi: 10.1038/s41598-018-37924-6.
Increased activity of brown adipose tissue (BAT) activity in adults is thought to prevent obesity. Therefore, regulators of BAT activity might serve as anti-obesity therapy in future, but are not investigated thoroughly up to now. In our study, we assessed retrospectively the association of BAT activity with several external factors and diverse chemotherapeutic and immunosuppressive agents in a collective of 702 patients. The patients underwent at least two clinically indicated PET/CT examinations in the course of different oncological and inflammatory diseases. BAT activity was identified according to predefined PET/CT criteria in all examinations. In multivariate analysis, the type of disease, the disease activity and the therapeutic regimen did not influence BAT activity. In contrast, sex and age were confirmed as independent factors for BAT activity. For the association of therapeutic agents with BAT activity, we examined 53 different disease-related agents, which were applied to patients without initial BAT activity between their PET/CT examinations. Out of these, cytarabine therapy was significantly associated with increased new onset of BAT activity. Cytarabine is a therapeutic agent for lymphoma patients. Further targeted studies might investigate the usefulness of Cytarabine serving as possible therapeutic approach against obesity via BAT regulation.
棕色脂肪组织 (BAT) 活性增加被认为可以预防肥胖。因此，BAT 活性调节剂可能成为未来的抗肥胖疗法，但迄今为止尚未得到充分研究。在我们的研究中，我们回顾性评估了 BAT 活性与 702 名患者的多种外部因素和多种化疗和免疫抑制药物之间的关联。这些患者在不同的肿瘤和炎症性疾病过程中至少进行了两次临床指示的 PET/CT 检查。根据所有检查中的预设 PET/CT 标准确定 BAT 活性。在多变量分析中，疾病类型、疾病活动度和治疗方案并不影响 BAT 活性。相反，性别和年龄被确认为 BAT 活性的独立因素。对于治疗药物与 BAT 活性的关联，我们检查了 53 种不同的与疾病相关的药物，这些药物在患者的 PET/CT 检查之间没有初始 BAT 活性时应用。在这些药物中，阿糖胞苷治疗与新出现的 BAT 活性增加显著相关。阿糖胞苷是一种用于治疗淋巴瘤患者的药物。进一步的靶向研究可能会研究阿糖胞苷作为通过 BAT 调节治疗肥胖的潜在治疗方法的有用性。
